Results published today in JAMA Oncology suggest post-operative radiation and hormone therapy, before cancer recurrence, as a new prostate cancer treatment option for men with a Gleason Score of 9 or 10.
In castration-resistant prostate cancer, the tumors continue to progress even though testosterone production has been blocked; more than 90% of these patients develop metastasis and the survival rate is one to two years. * Using liquid biopsy, a simple blood test has been successful in determining what type of treatment can help to prolong the life expectancy of more than 150 patients
Phone calls are more effective reminders for patients to book cancer screening appointments than mailed letters but are also more costly, suggests a new study from St. Michael's Hospital.
A nuclear medicine imaging procedure can pinpoint prostate cancer with superior accuracy, allowing more precisely targeted treatment, according to new research featured in the November 2018 issue of The Journal of Nuclear Medicine.
Androgen deprivation therapy was associated with a 72 percent higher risk of heart failure in a study of patients with prostate cancer.
Men who have been newly diagnosed with prostate cancer say they would trade some improvement in their odds of survival for improvements in side effects and quality of life, according to research presented at the 2018 NCRI Cancer Conference.
Researchers at the George Washington University found skin cooling methods may be the best preventative intervention against taxane-based chemotherapy side effects.
For most cancers, risk increases dramatically with age. But what about the effect of having more cells in the body? Might taller people be more prone to cancer because they have more cells? Yes, according to Leonard Nunney, an evolutionary biologist at the University of California, Riverside, who examined data from four large-scale surveillance projects on 23 cancer categories.
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used safely in oligometastatic patients with multiple metastases.
A new type of molecule blocks the action of genes that drive the growth of therapy-resistant prostate cancer.